![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
ALTANA Pharma |
Information provided by: | ALTANA Pharma |
ClinicalTrials.gov Identifier: | NCT00163423 |
The aim of the study is to compare the efficacy of ciclesonide versus fluticasone propionate on lung function, time to first asthma exacerbation, asthma symptoms, use of rescue medication, and quality of life in patients with mild to moderate asthma. Ciclesonide will be inhaled at one dose level once daily; fluticasone propionate will be inhaled at one dose level twice daily. The study duration consists of a baseline period (2 to 4 weeks) and a treatment period (24 weeks). The study will provide further data on safety and tolerability of ciclesonide.
Condition | Intervention | Phase |
Asthma |
Drug: Ciclesonide |
Phase III |
MedlinePlus related topics: | Asthma |
ChemIDplus related topics: | Fluticasone propionate Fluticasone Ciclesonide |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Comparison of Ciclesonide (80 Mcg Once Daily in the Evening) and Fluticasone Propionate (100 Mcg Twice Daily) in Patients With Mild to Moderate Asthma |
Estimated Enrollment: | 480 |
Study Start Date: | November 2004 |
Ages Eligible for Study: | 12 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Main Inclusion Criteria:
Main Exclusion Criteria:
![]() |
Show 51 Study Locations |
ALTANA Pharma |
Principal Investigator: | Ronald Dahl, Prof. | Aarhus University Hospital, Aarhus, Denmark |
Study ID Numbers: | BY9010/M1-142 |
First Received: | September 12, 2005 |
Last Updated: | July 16, 2008 |
ClinicalTrials.gov Identifier: | NCT00163423 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
|
|
|
|
|
![]() |